NCT06585449 - A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 14, 2024

Primary Completion Date

July 5, 2028

Study Completion Date

July 5, 2028

Conditions

Huntington's Disease

Interventions

DRUG

ALN-HTT02

ALN-HTT02 will be administered intrathecally

DRUG

Placebo

Placebo will be administered intrathecally

Trial Locations (17)

Unknown

RECRUITING

Clinical Trial Site, Edmonton

RECRUITING

Clinical Trial Site, Montreal

RECRUITING

Clinical Trial Site, Ottowa

RECRUITING

Clinical Trial Site, Vancouver

RECRUITING

Clinical Trial Site, Bayern

RECRUITING

Clinical Trial Site, Bochum

RECRUITING

Clinical Trial Site, Bonn

RECRUITING

Clinical Trial Site, Venusberg

RECRUITING

Clinical Trial Site, Birmingham

RECRUITING

Clinical Trial Site, Cambridge

RECRUITING

Clinical Trial Site, Cardiff

RECRUITING

Clinical Trial Site, Glasgow

RECRUITING

Clinical Trial Site, London

RECRUITING

Clinical Trial Site, Manchester

RECRUITING

Clinical Trial Site, Oxford

RECRUITING

Clinical Trial Site, Plymouth

01307

RECRUITING

Clinical Trial Site, Dresden